Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Probi AB (publ)    PROB   SE0001280355


Real-time Estimate Quote. Real-time Estimate BATS EUROPE - 11/26 03:08:41 pm
382.7500 SEK   -2.48%
10/21Q3 2020 : Strong growth with good profitability
10/20PROBI : acquires shares in Vital Nutrients Holdings and enters into strategic partnership
10/19PROBI : Presentation of Probi's Q3 report
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Q3 2020: Strong growth with good profitability

10/21/2020 | 02:01am EST

Significant events during the third quarter

· Net sales increased by 38% (43% adjusted for currency changes) to SEK 195 m (142). Positive one-off effect of around SEK 15 m from an American customer's product update program.
· The EBITDA margin was 32% (32%).
· New vice president R&D recruited starting September.
· New research study with Lund University published showing a link between probiotics and reduced side-effects from stress.

Significant events after the end of the period

· Acquisition of shares in Vital Nutrients Holdings and entering into strategic partnership. Total amount of USD 6 m with an ownership slightly below 10%.

CEO's comments
We're on a growth journey

We delivered the strongest quarter in our history with sales growth of 38% compared with last year. Growth was mainly driven by Americas, which had a strong quarter. The EBITDA margin for the group in the third quarter was 32%, which is on a par with last year, and for the nine-month period we had an EBITDA margin of 28%.

Demand for our products continues to be strong in Americas and the negative effects of COVID-19 have been limited. The strong growth in the region of 50% over the quarter is partly explained by the product update that one of our major customers is carrying out, but the majority of our growth comes from increased demand from both existing and new customers. We continue to view our growth opportunities in Americas positively, but at the same time note that variations between quarters can occur depending on how customer orders fall.

Developments in EMEA and APAC have been weaker, with the regions being negatively affected by the stock building up that took place during the previous quarter, driven by the COVID-19 pandemic. Although we judge that these are temporary fluctuations, we are not satisfied with the performance. We have taken measures, especially in our organization in Asia, and see continued strong growth potential in the region.

Our investment program in the manufacturing facilities in the US is developing according to plan. With these investments made, we will have a stronger production capacity next year and at the same time be able to reduce production costs, which is expected to lead to a positive effect on the gross margin.

Exploring new product areas continues and in August we were able to publish a research study, together with Lund University, which shows a link between probiotics and reduced side effects of acute psychosocial stress. This is potentially a very exciting area where we see attractive opportunities in the future.

I am pleased to now have a complete management team at Probi following our latest recruitment of Peter Dybdahl Hede as the new Vice President R&D. Peter took up his position in September and has extensive experience in R&D from the biotech and pharmaceutical industries.

On the 20th October we announced our acquisition of shares in Vital Nutrients Holdings. The acquisition is part of a strategic partnership with great potential to get leverage on our operations within the companies in the Vital Nutrients Holdings.

Our employees have shown an amazing ability to handle this exceptional time. Although we have all had to challenge ourselves and find new, creative solutions, we have not lost focus. The level of activity at Probi is high in all areas and with the deal with Vital Nutrients Holdings we show our commitment to reach our growth target.

Tom Rönnlund

Invitation to teleconference

Probi's interim report for Q3 2020 was published on October 21, 2020 at 8.00 am. On the same day at 10.00, a teleconference will be held with Tom Rönnlund, CEO and Henrik Lundkvist, CFO, who will present the report. The conference call can be reached on telephone number +46 (0)8 50 55 83 68. The presentation is available at www.probi.com and www.financialhearings.com


Tom Rönnlund, CEO, Tel: +46 (0)46 286 89 40, Email: trd@probi.com               
Henrik Lundkvist, CFO, Tel: +46 (0)46 286 89 41, Email: henrik.lundkvist@probi.com

This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the CEO and CFO, on October 21, 2020 at 08:00 CET. This a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.



(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) 1.53% 398.5 Delayed Quote.76.80%
SYMRISE AG 0.73% 103.35 Delayed Quote.9.38%
All news about PROBI AB (PUBL)
10/21Q3 2020 : Strong growth with good profitability
10/20PROBI : acquires shares in Vital Nutrients Holdings and enters into strategic pa..
10/19PROBI : Presentation of Probi's Q3 report
08/27PROBI : New clinical results on stress from Probi and their probiotic strain L. ..
07/17Q2 2020 : Probi raises long-term financial targets
07/14PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
07/14PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
07/02PROBI PUBL : and Örebro University to collaborate on research into exploration o..
05/14PROBI PUBL : A true pioneer in probiotic research is elected NutraChampion 2020
05/14PROBI AB (PUBL) : Ex-dividend day for final dividend
More news
Sales 2020 713 M 83,4 M 83,4 M
Net income 2020 103 M 12,1 M 12,1 M
Net cash 2020 261 M 30,5 M 30,5 M
P/E ratio 2020 43,3x
Yield 2020 0,41%
Capitalization 4 472 M 525 M 524 M
EV / Sales 2020 5,91x
EV / Sales 2021 5,35x
Nbr of Employees -
Free-Float 38,9%
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts 2
Average target price 440,00 SEK
Last Close Price 392,50 SEK
Spread / Highest target 12,1%
Spread / Average Target 12,1%
Spread / Lowest Target 12,1%
EPS Revisions
Tom Juhani Rönnlund Chief Executive Officer
Jean-Yves Parisot Chairman
Andy McShea Vice President-Operations
Henrik Lundkvist Chief Financial Officer
Niklas Brandt Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
PROBI AB (PUBL)76.80%525
BY-HEALTH CO., LTD.55.19%6 158
MEDIFAST, INC.75.84%2 277